Patents by Inventor James C. Lanter

James C. Lanter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Progranulin Modulators and Methods of Using the Same
    Publication number: 20230406843
    Abstract: Provided herein are compounds that modulate progranulin and methods of using the compounds in progranulin-associated disorders, such as Frontotemporal lobe dementia (FTLD).
    Type: Application
    Filed: December 10, 2021
    Publication date: December 21, 2023
    Inventors: Duane A. Burnett, James C. Lanter
  • PROGRANULIN MODULATORS AND METHODS OF USING THE SAME
    Publication number: 20230115534
    Abstract: Provided herein are compounds that modulate progranulin and methods of using the compounds in progranulin-associated disorders, such as Frontotemperal lobe dementia (FTLD).
    Type: Application
    Filed: December 18, 2020
    Publication date: April 13, 2023
    Inventors: Duane A. Burnett, James C. Lanter, Johannes Paulus Gerardus Seerden, Wim Zonneveld, Roel Peter Liesbeth Bell
  • PROGRANULIN MODULATORS AND METHODS OF USING THE SAME
    Publication number: 20220409593
    Abstract: Provided herein are compounds of formula (I) that modulate progranulin and methods of using the compounds in progranulin-associated disorders, such as Frontotemperal lobe dementia (FTLD).
    Type: Application
    Filed: October 23, 2020
    Publication date: December 29, 2022
    Inventors: Duane A. Burnett, James C. Lanter
  • 5,8-DISUBSTITUTED-[1,2,4]TRIAZOLO[1,5-A]PYRIDINYL AND 5,8-DISUBSTITUTED-IMIDAZO[1,2-A]PYRIDINE DERIVATIVES USEFUL AS INHIBITORS OF ENTEROPEPTIDASE
    Publication number: 20220281866
    Abstract: The present invention is directed to 5,8-disubstituted-[1,2,4]triazolo[1,5-a]pyridinyl and 5,8-disubstituted-imidazo[1,2-a]pyridine derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the enteropeptidase enzyme.
    Type: Application
    Filed: July 17, 2020
    Publication date: September 8, 2022
    Inventors: Xuqing Zhang, Weimei Sun, James C. Lanter, Brahmananda Ghosh
  • PROGRANULIN MODULATORS AND METHODS OF USING THE SAME
    Publication number: 20220251084
    Abstract: Provided herein are compounds that modulate progranulin and methods of using the compounds in progranulin-associated disorders, such as Frontotemporal dementia (FTD).
    Type: Application
    Filed: June 12, 2020
    Publication date: August 11, 2022
    Inventors: Duane A. Burnett, William J. Greenlee, James C. Lanter
  • Cylcoalkenyl derivatives useful as agonists of the GPR120 and/or GPR40 receptors
    Patent number: 11230526
    Abstract: The present invention is directed to cycloalkenyl derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the GPR120 and/or GPR40 receptors. More particularly, the compounds of the present invention are agonists of GPR120 and/or GPR40, useful in the treatment of, for example, obesity, Type II Diabetes Mellitus, dyslipidemia, etc.
    Type: Grant
    Filed: March 5, 2019
    Date of Patent: January 25, 2022
    Assignee: Janssen Pharmaceutica NV
    Inventors: James C. Lanter, Mark J. Macielag, Mark Wall, Michael P. Winters, Yue-Mei Zhang, Zhihua Sui
  • Cyclohexyl GPR40 agonists for the treatment of type II diabetes
    Patent number: 10988433
    Abstract: Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR40 receptor. Such compounds are represented by Formula (I) as follows: wherein R1, R2, R3, A, W, L, Ra, and G are defined herein: and by Formula (II) as follows: wherein R1B, WB, LB, , and GB are defined herein.
    Type: Grant
    Filed: October 24, 2017
    Date of Patent: April 27, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Hui Huang, James C. Lanter, Sanath K. Meegalla, Mark R. Player
  • HETEROCYLCOALKENYL DERIVATIVES USEFUL AS AGONISTS OF THE GPR120 AND / OR GPR40
    Publication number: 20210024483
    Abstract: The present invention is directed to heterocycloalkenyl derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the GPR120 and/or GPR40 receptors. More particularly, the compounds of the present invention are agonists of GPR120 and/or GPR40, useful in the treatment of, for example, obesity, Type II Diabetes Mellitus, dyslipidemia, etc.
    Type: Application
    Filed: March 5, 2019
    Publication date: January 28, 2021
    Inventors: James C. Lanter, Mark Wall, Zhihua Sui
  • CYCLOHEXYL GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES
    Publication number: 20200039914
    Abstract: Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR40 receptor. Such compounds are represented by Formula (I) as follows: wherein R1, R2, R3, A, W, L, Ra, and G are defined herein: and by Formula (II) as follows: wherein R1B, WB, LB, , and GB are defined herein.
    Type: Application
    Filed: October 24, 2017
    Publication date: February 6, 2020
    Inventors: Hui Huang, James C. Lanter, Sanath K. Meegalla, Mark R. Player
  • Indole derivatives as selective androgen receptor modulators (SARMS)
    Patent number: 9434688
    Abstract: The present invention is directed to novel indole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the androgen receptor.
    Type: Grant
    Filed: May 14, 2014
    Date of Patent: September 6, 2016
    Assignee: Janssen Pharmaceutica NV
    Inventors: James C Lanter, Zhihua Sui, James J Fiordeliso, Weiqin Jiang, Xuqing Zhang
  • 2-substituted benzimidazoles as selective androgen receptor modulators (SARMS)
    Patent number: 9120830
    Abstract: The present invention is directed to a novel 2-substituted benzimidazole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the androgen receptor.
    Type: Grant
    Filed: June 27, 2014
    Date of Patent: September 1, 2015
    Assignee: Janssen Pharmaceutica NV
    Inventors: Vernon C Alford, Jr., James C Lanter, Raymond A Ng
  • Cyclohexyl-azetidinyl antagonists of CCR2
    Patent number: 9062048
    Abstract: The present invention comprises compounds of Formula I. wherein: R1, R2, R4, J, Q, and A are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.
    Type: Grant
    Filed: July 22, 2013
    Date of Patent: June 23, 2015
    Assignee: Janssen Pharmaceutica NV
    Inventors: James C. Lanter, Thomas P. Markotan, Nalin Subasinghe, Zhihua Sui
  • 4-substituted-cyclohexylamino-4-piperidinyl-acetamide antagonists of CCR2
    Patent number: 8921559
    Abstract: The present invention comprises compounds of Formula (I). wherein: R1, R2, R3, R4, X, Y, and Z are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula (I).
    Type: Grant
    Filed: November 30, 2011
    Date of Patent: December 30, 2014
    Assignee: Janssen Pharmaceutica NV
    Inventors: James C. Lanter, Thomas P. Markotan, Nalin Subasinghe, Zhihua Sui, Xuqing Zhang
  • NOVEL 2-SUBSTITUTED BENZIMIDAZOLES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS)
    Publication number: 20140309261
    Abstract: The present invention is directed to a novel 2-substituted benzimidazole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the androgen receptor.
    Type: Application
    Filed: June 27, 2014
    Publication date: October 16, 2014
    Inventors: Vernon C. Alford, JR., James C. Lanter, Raymond A. Ng
  • NOVEL INDOLE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS)
    Publication number: 20140249197
    Abstract: The present invention is directed to novel indole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the androgen receptor.
    Type: Application
    Filed: May 14, 2014
    Publication date: September 4, 2014
    Applicant: Janssen Pharmaceutica, NV
    Inventors: James C. Lanter, Zhihua Sui, James J. Fiordeliso, Weiqin Jiang, Xuqing Zhang
  • 2-substituted benzimidazoles as selective androgen receptor modulators (SARMS)
    Patent number: 8802865
    Abstract: The present invention is directed to a novel 2-substituted benzimidazole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the androgen receptor.
    Type: Grant
    Filed: October 1, 2013
    Date of Patent: August 12, 2014
    Assignee: Janssen Pharmaceutica, NV
    Inventors: Vernon C Alford, Jr., James C Lanter, Raymond A Ng
  • Indole derivatives as selective androgen receptor modulators (SARMS)
    Patent number: 8765782
    Abstract: The present invention is directed to novel indole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the androgen receptor.
    Type: Grant
    Filed: February 17, 2010
    Date of Patent: July 1, 2014
    Assignee: Janssen Pharmaceutica, NV
    Inventors: James C. Lanter, Zhihua Sui, James J. Fiordeliso, Weiqin Jiang, Xuqing Zhang
  • NOVEL 2-SUBSTITUTED BENZIMIDAZOLES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS)
    Publication number: 20140031317
    Abstract: The present invention is directed to a novel 2-substituted benzimidazole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the androgen receptor.
    Type: Application
    Filed: October 1, 2013
    Publication date: January 30, 2014
    Applicant: Janssen Pharmaceutica, NV
    Inventors: Vernon C Alford, JR., James C. Lanter, Raymond A. Ng
  • CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2
    Publication number: 20130310365
    Abstract: The present invention comprises compounds of Formula I. wherein: R1, R2, R4, J, Q, and A are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.
    Type: Application
    Filed: July 22, 2013
    Publication date: November 21, 2013
    Applicant: Janssen Pharmaceutical NV
    Inventors: James C. Lanter, Thomas P. Markotan, Nalin Subasinghe, Zhihua Sui
  • Benzimidazole derivatives useful as selective androgen receptor modulators (SARMS)
    Patent number: 8586616
    Abstract: The present invention is directed to novel benzimidazole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the androgen receptor.
    Type: Grant
    Filed: December 16, 2010
    Date of Patent: November 19, 2013
    Assignee: Janssen Pharmaceutica, NV
    Inventors: Raymond Ng, Zhihua Sui, Jihua Guan, James C. Lanter, Vernon C. Alford, Jr.